RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma

Patent metadata

Field	Value
Publication number	US-9550994-B2
Application number	US-201514692402-A
Country	US
Kind code	B2
Filing date	Apr 21, 2015
Priority date	Mar 11, 2005
Publication date	Jan 24, 2017
Grant date	Jan 24, 2017

Abstract

RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.

First claim

What is claimed is:

1. A composition comprising a double strand interfering RNA having a sense strand and an antisense strand wherein both the sense strand and the antisense strand are each 19 to 49 nucleotides in length, and wherein the antisense strand comprises a nucleotide sequence 100% complementary to nucleotides 1-19 of SEQ ID NO:18, SEQ ID NO: 98, or SEQ ID NO: 192; and a pharmaceutically acceptable carrier.

2. The composition of claim 1 , wherein the interfering RNA is an shRNA, an siRNA, or an miRNA.

3. The composition of claim 1 , further comprising a second interfering RNA targeted to the Frizzled Related Protein-1 mRNA.

4. The composition of claim 1 , wherein the sense strand and the antisense strand are connected by a loop.

5. The composition of claim 4 , wherein the loop consists of a nucleotide strand.

6. The composition of claim 1 , wherein the sense strand contains one or more chemically modified nucleotides, one or more deoxyribonucleotides, and/or one or more non-phosphodiester linkages, and a pharmaceutically acceptable carrier.

7. The composition of claim 1 , wherein the antisense strand contains one or more chemically modified nucleotides, one or more deoxyribonucleotides, and/or one or more non-phosphodiester linkages, and a pharmaceutically acceptable carrier.

8. The composition of claim 1 , wherein the sense strand and the antisense strand each contains one or more chemically modified nucleotides, one or more deoxyribonucleotides, and/or one or more non-phosphodiester linkages, and a pharmaceutically acceptable carrier.

Assignees

• Arrowhead Res Corp
• Arrowhead Pharmaceuticals Inc

Inventors

• Clark Abbot F
• Wang Wan-Heng
• Mcnatt Loretta Graves
• Chatterton Jon E

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C12N2310/316

  Phosphonothioates · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12N2310/351

  Conjugate · CPC title